ESMO WCGIC 2020 | Regorafenib + nivolumab in MMR proficient advanced CRC

Richard D. Kim • 3 Jul 2020

ESMO WCGIC 2020

Colorectal Cancer Gastrointestinal Cancer Antibodies Nivolumab Regorafenib

Immuno-Oncology

Richard Kim, MD, Moffitt Cancer Center, Tampa, FL, discusses results of a Phase I/IB study of regorafenib and nivolumab in mismatch repair proficient advanced refractory colorectal cancer. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

The challenges in implementing CAR-T cell therapy for the treatment of solid tumors

Richard D. Kim • 27 Jan 2022

Anti-EGFR therapy for RAS wild-type left-sided colorectal cancer

Richard D. Kim • 6 Jun 2022

80mg regorafenib plus pembrolizumab for 1L HCC

Richard D. Kim • 10 Jun 2021

Regorafenib in refractory biliary tract cancer

Richard D. Kim • 3 Jul 2020

Related Videos

EuropaColon survey of the unmet needs of metastatic colorectal cancer patients

Geoffrey Henning • 3 Mar 2017

Novel developments in HCC treatment

Daneng Li • 6 Jul 2020

COVID-19 & the management of cancer patients

Alberto F. Sobrero • 3 Jun 2020

Treatment landscape for HCC

Arndt Vogel • 9 Nov 2018